People · Operator
Named in public records as an officer, director or promoter · active 2010–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alpine Immune Sciences, Inc. | — | Biotechnology | Series C | $234.9M | $2.3B | 2019 |
| Immune Design Corp. | — | Biotechnology | Series C | $144.6M | $2.0B | 2010 |
| Sound Pharmaceuticals Inc | — | Biotechnology | Series A | $21.6M | $304.0M | 2015 |
James Paul Rickey at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Paul Rickey on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Miller | 1 | 29 |
| John Moore | 1 | 12 |
| Jonathan Leff | 1 | 11 |
| David Guyer | 1 | 8 |
| Richard Klausner | 1 | 7 |
| Brian Atwood | 1 | 6 |
| Jay Venkatesan | 1 | 5 |
| James C. Towne | 1 | 4 |
| Paul Thompson | 1 | 3 |
| Joseph Ashley | 1 | 3 |
| Joseph Loscalzo | 1 | 3 |
| Alain Schreiber | 1 | 3 |
| David Baltimore | 1 | 2 |
| Edward Penhoet | 1 | 2 |
| John C. Sullivan | 1 | 2 |
| Evan Loh | 1 | 2 |
| Howard Furst | 1 | 2 |
| Glenn Kawasaki | 1 | 2 |
| Peter V. Svennilson | 1 | 2 |
| Steven Reed | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.